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ABSTRACT
Objective The choice of adequate proxy for long-term
survival, the ultimate outcome in randomised clinical
trials (RCT) assessing disease-modifying treatments for
amyotrophic lateral sclerosis (ALS), is a key issue. The
intrinsic limitations of the ALS Functional Rating Scale-
Revised (ALSFRS-R), including non-linearity,
multidimensionality and floor-effect, have emerged and
its usefulness argued. The ALS Milano-Torino staging
(ALS-MITOS) system was proposed as a novel tool to
measure the progression of ALS and overcome these
limitations. This study was performed to validate the
ALS-MITOS as a 6-month proxy of survival in 200 ALS
patients followed up to 18 months.
Methods Analyses were performed on data from the
recombinant human erythropoietin RCT that failed to
demonstrate differences between groups for both
primary and secondary outcomes. The ALS-MITOS system
is composed of four key domains included in the
ALSFRS-R scale (walking/self-care, swallowing,
communicating and breathing), each with a threshold
reflecting the loss of function in the specific ALSFRS-R
subscores. Sensitivity, specificity and the area under the
curve of the receiver operating characteristic curves of
the ALS-MITOS system stages and ALSFRS-R decline at 6
months were calculated and compared with the primary
outcome (survival, tracheotomy or >23-hour non-
invasive ventilation) at 12 and 18 months Predicted
probabilities of the ALS-MITO system at 6 months for
any event at 12 and 18 months were computed through
logistic regression models.
Results Disease progression from baseline to 6 months
as defined by the ALS-MITOS system predicted death,
tracheotomy or >23-hour non-invasive ventilation at 12
months with 82% sensitivity (95% CI 71% to 93%,
n=37/45) and 63% specificity (95% CI 55% to 71%,
n=92/146), and at 18 months with 71% sensitivity
(95% CI 61% to 82%, n=50/70) and 68% specificity
(95% CI 60% to 77%, n=76/111). The analysis of ALS-
MITOS and ALSFRS-R progression at 6-month follow-up
showed that the best cut-off to predict survival at 12
and 18 months was 1 for the ALS-MITOS (ie, loss of at
least one function) and a decline ranging from 6 to 9
points for the ALSFRS-R.
Conclusions The ALS-MITOS system can reliably
predict the course of ALS up to 18 months and can be
considered a novel and valid outcome measure in RCTs.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neuro-
degenerative disease leading to the majority of
patients dying within a limited number of years.1 2
The disability score ALS Functional Rating
Scale-Revised (ALSFRS-R)3 has been used to
measure the course of the disease and to assess the
efficacy of candidate treatments in clinical trials.4–8
However, its ability to be a reliable outcome in
disease-modifying clinical trials has been argued
due to the following limitations: (1) non-linear,
thus prone to biases;9 (2) multidimensional, thus
unfit as single score and unable to satisfy rigorous
measurement standards;9 (3) floor-effect, thus
unable to capture late-stage clinical changes.1 10 11
Recently, the ALS Milano-Torino staging
(ALS-MITOS) system was proposed as a novel tool
to measure the progression of ALS.1 The
ALS-MITOS system, which is based on the assess-
ment of four functional domains assayed by the
ALSFRS-R, was found to reliably identify relevant
stages of disease in patients according to the
number of functions lost, to be consistent with
sequential disease progression, to overcome non-
linearity and multidimensionality features of
ALSFRS-R, and to correlate well with patients’
quality of life and health service costs.1 This study
aimed to confirm the robustness of the
ALS-MITOS system and validate its ability to be a
proxy of long-term survival.
METHODS
Patients and measures
Data were derived from a randomised, double-
blind, placebo-controlled clinical trial (RCT) on the
efficacy of recombinant human erythropoietin in
ALS that failed to demonstrate differences between
active treatment and placebo, in primary and in
secondary outcomes.12 Briefly, patients aged
18–75 years and diagnosed with probable
laboratory-supported, probable or definite ALS
according to El Escorial revised criteria were
enrolled in 25 Italian ALS centres. Inclusion criteria
were onset ≤18 months and slow vital capacity
≥70% of predicted value at the screening visit. The
primary outcome was time to death, tracheotomy
or >23 h non-invasive ventilation (NIV) daily for
14 consecutive days at 12 months. Development
and evaluation of the ALS-MITOS system have
been previously described.1 Briefly, four key
domains included in the ALSFRS-R scale (walking/
self-care, swallowing, communicating and breath-
ing) were selected to obtain a tool capable of cap-
turing the lost functions. Each domain has a
threshold reflecting the loss of function in the spe-
cific ALSFRS-R subscores. Values of 0 (below
threshold) or 1 (above threshold) were assigned,
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and the stages were determined as the sum of those values
across the four domains. Five stages were defined: stage 0 indi-
cates functional involvement and no loss of function in any
domain; stages 1–4 represent the number of domains in which
function was lost; and stage five is death (see online supplemen-
tary table).1
Statistical analysis
Baseline patients’ features were reported as percentages for
dichotomous data, means with SD and medians with value
range for continuous data. The ALS-MITOS system was
reported using descriptive statistics for each participant at base-
line, and at 6-month and 12-month follow-up. Sensitivity and
specificity with the corresponding 95% CI, and the area under
the curve of the receiver operating characteristic (ROC) curves
of the ALS-MITOS system stages as well as ALSFRS-R decline at
6 months were calculated, and compared to the primary
outcome (survival, tracheotomy or >23 h NIV) at 12 and
18 months, where an event was defined by the occurrence of at
least one among the three. Predicted probability with the corre-
sponding 95% CI of the ALS-MITO system at 6 months for any
event at 12 and 18 months was computed through logistic
regression models.
RESULTS
Among the 200 patients randomised, nine withdrew consent
before 6-month follow-up and five between 6-month and
12-month follow-up (figure 1). Table 1 reports patients’ demo-
graphic and clinical features at the baseline visit. In the analysis
of progression based on the ALS-MITOS system, 153 of 200
patients (76.5%) at baseline were in stage 0 and 44 patients
(22%) were in stage 1, while only three patients (1.5%) were in
stage 2 and none in stage 4. Among the 44 patients in stage 1,
38 (86.4%) had lost function in walking/self-care, 3 (6.8%) in
breathing, 2 (4.6%) in swallowing and 1 (2.3%) in communicat-
ing. Among the 191 patients who performed the 6-month
follow-up visit or died, 91 (47.6%; 49.7% of 141 spinal and
42% of 50 bulbar onset patients, p=0.35) progressed to
advanced stages of disease (figure 2A). Among the 186 patients
who performed the 12-month follow-up visit or died, 136
(73.1%; 74.5% of 137 spinal and 69.4% of 49 bulbar onset
patients, p=0.49) progressed to advanced stages of disease and
50 (26.9%) did not. Overall, 42 patients (22.6%) were in stage
0, 50 patients (26.9%) were in stage 1, 34 patients (18.3%)
were in stage 2, 29 patients (15.6%) were in stage 3, nine
patients (4.8%) were in stage 4 and 22 patients (11.8%) were in
stage 5 (death). At 12 months, among the 122 subjects with at
least one function lost, 109 (89.3%) had loss of autonomy in
walking/self-care, 56 (45.9%) in breathing, 44 (36.1%) in swal-
lowing and 32 (26.2%) in communicating. Patients at stage 1 at
baseline had a higher, although non-statistically significant,
probability of transition to advanced stages (75%) or of dying
(20%) than those at stage 0 (70.6% and 9.8%, respectively,
p=0.07) (figure 2B). No transition to a lower stage of disease
was observed between baseline and 12 months (two patients
moved from stage 1 at baseline to stage 0 at 6 months and
returned to stage 1 at 12 months, due to fluctuations in walking/
self-care domain).
Figure 1 Flow-chart.
Table 1 Baseline characteristics
Characteristic N=200
Demographic characteristics
Female, n (%) 95 (47.5%)
Age, years
Mean±SD 59±10
Median (range) 61 (25–75)
Clinical characteristics
Time since ALS onset, years
Mean±SD 1.0±0.4
Median (range) 1.1 (0.2–1.7)
ALS onset type, n (%)
Spinal 148 (74.0%)
Bulbar 52 (26.0%)
ALSFRS-R score at entry
Mean±SD 38.3±5.8
Median (range) 39 (20–48)
ALS, amyotrophic lateral sclerosis; ALSFRS-R, Amyotrophic Lateral Sclerosis Functional
Rating Scale-Revised.
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The analysis for any stage of disease progression from baseline
to 6-month follow-up showed sensitivity of 82% (95% CI 71%
to 93%, n=37/45), specificity of 63% (95% CI 55% to 71%,
n=92/146), a positive predictive value of 41% and a negative
predictive value of 92% of the ALS-MITOS system for the
primary outcome (death, tracheotomy or >23 h NIV) at
12 months. In other words, based on the disease worsening at
6 months from the first observation at baseline, irrespective of
the number of functions lost at 6 months, the ALS-MITOS
system was able to correctly identify one patient who would
have an event included in the primary outcome at 12 months
with a probability of 82%. At the same time, the system was
able to correctly identify with a probability of 63% one patient
who would not have an event included in the primary outcome.
When we analysed the number of functions lost at 6 months
compared with baseline, the ALS-MITOS system was found to
have a probability to predict the primary outcome at 12 months
with sensitivity of 62% and specificity of 67% in patients who
advanced by 1 stage (eg, from stage 0 to 1, or from 1 to 2, etc),
and of 62% and 94%, respectively, in those who advanced by
two stages (eg, from stage 0 to 2, or from 2 to 4, etc). The cor-
responding positive predictive values were 22% for patients
who advanced by one stage and 68% for those who advanced
by two stages, showing a higher probability to have an event at
12 months for patients who advanced by two stages compared
to a progression of one stage.
The corresponding analysis at 18 months for any stage of pro-
gression from baseline to 6 months showed sensitivity of 71%
(95% CI 61% to 82%, n=50/70), specificity of 68% (95% CI
60% to 77%, n=76/111), a positive predictive value of 59%
and a negative predictive value of 79% of the ALS-MITOS
system for the primary outcome (death, tracheotomy or >23 h
NIV). When we analysed the number of functions lost at
6 months compared with baseline, the ALS-MITOS system was
found to have a probability to predict the primary outcome at
18 months with sensitivity of 52% and specificity of 71% in
patients who advanced by one stage (eg, from stage 0 to 1, or
from 1 to 2, etc), and of 44% and 96%, respectively, in those
who advanced by two stages (eg, from stage 0 to 2, or from 2
to 4, etc).
The comparison between ALS-MITOS system progression
and ALSFRS-R decline over the first 6 months from baseline
showed that the area under the ROC curves of the ALSFRS-R
decline was slightly higher than that of the ALS-MITOS system
progression at both 12 months (0.87 and 0.81, respectively) and
18 months (0.84 and 0.75, respectively) (figure 3).
The corresponding values adjusted by the baseline ALSFRS-R
score did not significantly change (0.88 and 0.83 for the
ALSFRS-R and ALS-MITOS system, respectively, at 12 months;
0.85 and 0.79 for the ALSFRS-R and ALS-MITOS system,
respectively, at 18 months). Based on these curves, the best
Figure 2 ALS stage at 6 months (A) and at 12 months (B) by baseline
stage. ALS, amyotrophic lateral sclerosis.
Figure 3 ROC curves for (A) ALSFRS-R decline and ALS-MITO staging
progression from baseline to 6 months versus primary outcome at
12 months, and (B) ALSFRS-R decline and ALS-MITO staging
progression from baseline to 6 months versus primary outcome at
18 months. ALS, amyotrophic lateral sclerosis; ALSFRS-R, Amyotrophic
Lateral Sclerosis Functional Rating Scale-Revised; ALS-MITO, ALS
Milano-Torino ; ROC, receiver operating characteristic.
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cut-off of the ALS-MITOS system to predict at 6 months the
primary outcome at 12 and 18 months was one (ie, loss of at
least one function from baseline to 6 months), whereas that of
the ALSRFS-R ranged between six to nine points of decline
(table 2).
As expected, we observed that the higher the stage of disease
based on the ALS-MITOS system at 6 months, the higher the
probability to reach the primary outcome within 12 and
18 months (figure 4). Irrespective of the stage of the disease at
6 months, the predicted probability to have an event included in
the primary outcome at 18 months was always higher than at
12 months. For example, patients who had lost two functions at
6 months had a predicted probability of about 40% to have an
event of the primary outcome within 12 months and of about
65% within 18 months.
DISCUSSION
The present study confirmed the validity and robustness of the
ALS-MITOS system to be consistent with sequential disease pro-
gression and revealed its ability to be a proxy of long-term
outcome. Moreover, it has demonstrated reliability and ease of
use across a large number of ALS centres. In particular, we
found that, according to the ALS-MITOS system, in our popula-
tion of 200 patients with ALS with an onset ≤18 months,
almost 50% at 6 months and more than 70% at 12-month
follow-up progressed to advanced stages of disease. According
to previous findings,1 the probability of transition from a given
stage was highest for the next higher stage, with the majority of
patients reporting a loss of function in walking/self-care (89%),
almost 50% in breathing and more than 30% in swallowing, at
12 months.
The progression of disease from baseline to 6 months as
defined by the ALS-MITOS system appeared to be a good proxy
of death, tracheotomy or >23 h NIV at 12-month and
18-month follow-up in terms of sensitivity and predicted prob-
ability. Furthermore, the ALS-MITOS system correlated well
with the 6-month ALSFRS-R decline, showing similar accuracy.
Accordingly, the analysis of the ROC curves demonstrated that,
compared to the best cut-off values of the ALSFRS-R decline
over 6 months (ie, values within the range from six to nine,
where six would be the best cut-off to increase sensitivity), the
best cut-off values of the ALS-MITOS system showed satisfac-
tory sensitivity and specificity values. Moreover, it should be
considered that there is no validated cut-off for the ALSFRS-R
and, mostly, that the clinical meaningfulness of a difference in
one or two points can be influenced by the baseline score of the
study population and, overall, may be hardly considered clinic-
ally meaningful.
During the past 7 years, 18 RCTs4–6 12–26 on 14 different
drugs were performed and failed to show positive results.
Although progressively better organised, all these RCTs showed
Table 2 Sensitivity and specificity, with the corresponding 95% CI, of the ALSFRS-R decline and the ALS-MITOS worsening from baseline to
6 months compared to the primary composite outcome (ie, survival, tracheotomy or >23 h non-invasive ventilation) at 12 and 18 months
Scale
Compared to primary outcome at 12 months
Compared to primary outcome at
18 months
Sensitivity
(95% CI)
Specificity
(95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
6-month ALSFRS-R decline
6 points 93%
(86% to 100%)
58%
(50% to 66%)
83%
(74% to 92%)
63%
(54% to 72%)
7 points 87%
(77% to 97%)
64%
(56% to 72%)
76%
(66% to 86%)
69%
(61% to 78%)
8 points 82%
(71% to 93%)
69%
(62% to 77%)
71%
(61% to 82%)
75%
(67% to 83%)
9 points 80%
(68% to 92%)
75%
(68% to 82%)
69%
(58% to 79%)
80%
(73% to 88%)
6-month ALS-MITOS system worsening
1 function 82%
(71% to 93%)
63%
(55% to 71%)
71%
(61% to 82%)
68%
(60% to 77%)
ALS, amyotrophic lateral sclerosis; ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; ALS-MITOS, ALS Milano-Torino staging.
Figure 4 Predicted probability with the corresponding 95% CI of
ALS-MITO staging at 6 months for event at 12 months (A) and at
18 months (B). ALS, amyotrophic lateral sclerosis; ALS-MITO, ALS
Milano-Torino.
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similar issues, which could have influenced the negative findings,
including the choice of the outcomes.27 28 The ultimate end
point in ALS is the time to death; however, it is not a feasible
outcome unless very long trials are designed. Indeed, more than
95% of patients enrolled in RCTs were alive at 6 months and
75–90% at 12 months.4–6 12–14 17 18 21 23 As emphasised in the
TCH346 trial,24 different clinical practice can influence survival,
beyond the need of more than 1000 patients followed up for
more than 3 years, to have an adequate power to use it as
primary outcome. To overcome this issue, that and many other
trials18 21 22 24 25 chose the mean ALSFRS-R decline as primary
outcome. However, ALSFRS-R also showed major limitations,
beyond the already mentioned non-linearity, multidimensional-
ity and inability to detect late-stage clinical changes.1 9–11
Indeed, a mean decline of one point/month up to 12 months
from randomisation was reported in all the longitudinal
studies,4–6 12–26 and a plateau between 12 and 18 months in the
only two studies including both those follow-up
periods,6 14 16 17 suggesting that the mean ALSFRS-R decline
cannot serve as a reliable outcome either at 6 months, since
only differences of one to three points between treatment
groups can be observed, or at 18 months, being unable to
capture slower changes in later stages. Consistently, the authors
of the glatiramer acetate trial conducted on 366 patients with
ALS,21 speculated that the choice of the ALSFRS-R decline as
primary outcome might be one of the reasons underlying the
negative results of the study, likely being either insensitive or
inappropriate.
A further important problem of the ALSFRS-R is how to con-
sider deaths. Accordingly, in the CoQ10 trial,22 the significantly
lower decline of the mean ALSFRS-R observed in the
CoQ10-treated arm was almost entirely driven by outlying
values from five deceased placebo patients, while the median
decline that is insensitive to outliers, was lower in the placebo
arm. Consistently, in the dexpramipexole trial,5 the authors
used as primary outcome a combined assessment of survival and
change from baseline in the ALSFRS-R score, emphasising that
the ALSFRS-R decline alone could not be proposed as primary
outcome due to the well known non-linearity over time, and
because it should be assumed that discontinuations, including
deaths, were random and non-informative.
Combined outcome measures including survival, tracheotomy,
NIV and/or selected domains of the ALSFRS-R scale showed
better performances compared to survival or mean ALSFRS-R
decline alone in several studies.4 5 12 17 19 20 For example, in
one of the lithium trials,19 the composite outcome of severe loss
of autonomy, defined as the time from inclusion to death/trache-
otomy or at least two of three selected ALSFRS-R scores (ie, ≤1
for swallowing, ≤1 for walking, or ≤2 for respiratory insuffi-
ciency), was able to capture a percentage of events around 15%
at 6 months and above 30% at 12 months. Similarly, in the
acetyl-L-carnitine trial,4 the composite primary outcome of loss
of self-sufficiency, defined as inability to swallow, cut food/
handle utensils and walk, was observed in more than 80% of
patients at 12 months.
The ALS-MITOS system1 was developed to be a reliable com-
posite outcome measure. The present study, performed to valid-
ate its use in RCTs, demonstrated its good correlation with
death, tracheotomy or >23 h NIV, as well as with the mean
ALSFRS-R decline over 6 months. Moreover, the ALS-MITOS
system can be a more clinically meaningful outcome in short-
term and medium-term trials compared with ALSFRS-R.
Indeed, it is based on the unidirectional progression of function
impairment in four key domains (walking/self-care, swallowing,
communicating and breathing), the achievement of which means
their loss without any possibility to recover.
What an ALS trial is expected to demonstrate in a time frame
useful to patients is that the candidate treatment can slow
(or hopefully halt) the progression of the disease. While it is
arguable to consider a drug that only prolongs survival by a few
months as efficacious, a difference of two-point decline over
6 months at the ALSFRS-R can hardly be considered clinically
meaningful. Moreover, the ALSFRS-R is not unequivocally uni-
directional, typically showing fluctuations over time that can be
due to treatments ameliorating certain symptoms (eg, drooling).
Conversely, a difference in terms of function lost or retained
can more reliably reflect the real effect of a treatment in ALS.
Our findings demonstrated that the ALS-MITOS system can reli-
ably correlate loss of functions at 6 months to survival at 12 and
18 months. Meeting the requirements of modern approaches to
ALS trials,28 it can be considered a novel and valid outcome
measure.
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